David Young, who serves as the President of Research & Development at Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), executed a recent purchase of the company's common stock. On May 15, 2026, Mr. Young acquired 1,545 shares, totaling $4,588 for the transaction, with each share purchased at a price of $2.97.
This latest acquisition contributed to his direct ownership stake in Processa Pharmaceuticals common stock. Following this specific purchase, Mr. Young's reported direct holding amount increased to 15,345 shares. This total figure accounts for adjustments made to correct immaterial errors identified during a Form 4 filing that occurred on May 1, 2026. The prior transaction being corrected was an earlier acquisition of stock that took place on April 30, 2026, which was recorded at a revised price of $2.71 per share.
Beyond his direct personal holdings, Mr. Young's total investment in the company is dispersed through various structured entities. Specifically, he holds shares amounting to 1,242 units via the Young-Plaisance Revocable Trust. Additional stakes are held through Family Entities, accounting for 432 shares, and another block of 742 shares managed by CorLyst, LLC.
Analysis available from InvestingPro suggests that the stock may currently be undervalued at its present levels. Furthermore, investors should note that the company's earnings results are scheduled to be released on May 22, providing a key date for market evaluation.
Key Insights from Insider Activity
The reported transaction highlights active participation by senior management in their own company's stock. The acquisition of shares by the President of Research & Development suggests internal conviction regarding Processa Pharmaceuticals' value proposition. This activity is generally interpreted as a signal of confidence, particularly when juxtaposed against upcoming corporate milestones like earnings releases.
The multiple holdings structures also define key investment points:
-
Risks
- Market reaction to upcoming earnings reports on May 22 remains an unknown variable.
- Shares are held through various trusts and entities (Young-Plaisance Revocable Trust, Family Entities, CorLyst, LLC), which adds layers of complexity to ownership structure.
- The recent correction of immaterial errors in prior Form 4 filings suggests administrative adjustments that investors should monitor for accuracy.
More from Insider Trading